Humacyte, Inc.HUMA

Sell some

Don't buy more at this price.

5 good· Earnings beat
4 to watch· Fewer buy ratings

$0.60+0.01 (+1.39%)

Price at 3:59 PM ET yesterday

After hours · opens in 17h 23m

NASDAQ · Healthcare · Very small company

Tell me when HUMA moves 5% in a day

Read the full report on HUMA with a free account

The full report adds the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.

−55.7% in a yearsince Nov 10, 2025

Earnings report

Latest results

Reported Tuesday before the open

EPS: −$0.07; vs −$0.09 expected, beat by $0.02 a share

Our call is still Sell some after the results.

The news behind our call

written yesterday, 6:28 PM ETYesterday, 6:28 PM ET · 17 articles · 8 sources

Humacyte’s third-quarter loss narrowed to $15.5 million, and EPS beat estimates.
Humacyte expects fourth-quarter Symvess sales to at least double.
Humacyte’s revenue growth is far above comparable companies.
Humacyte reported a smaller-than-expected third-quarter loss.

What changed

From Yahoo Finance, Humacyte, Inc. via Nasdaq, Humacyte, Inc. via Yahoo Finance and 2 more

Five presentations, one leading innovation: Humacyte’s Acellular Tissue Engineered Vessel takes Center Stage at VEITH 2026
Yesterday
Humacyte Q3 loss Narrows on lower R&D Costs; sees Symvess sales at Least Doubling in Q4
Yesterday
HUMA posted a 22.2% EPS beat, but financing risk still outweighs unproven profitability
Reported third-quarter EPS was -$0.07 versus -$0.09 estimated, a $0.02 or 22.2% beat on November 10, 2026. No explicit post-earnings guidance or management outlook was provided in the payload; guidance tone is unknown.
Earnings · Tuesday
Humacyte (HUMA) Q3 2026 earnings call transcript
Tuesday
Humacyte, Inc. Q3 2026 earnings call summary
Tuesday
Humacyte, Inc. (HUMA) Q3 2026 earnings call transcript
Tuesday
Humacyte Q3 earnings call highlights
Tuesday
Humacyte, Inc. (HUMA) reports Q3 loss, tops revenue estimates
Tuesday

Overview

In plain numbers

Revenue grew 53% from a year earlier, to $2.4M in the last twelve months.
It loses $45.74 on every revenue dollar at the operating line, up from a loss of $64.30 in FY 2021.
It burned $88.6M of free cash in the last twelve months.
It owes $66.5M and holds $64.5M in cash and investments, so net debt is $2.0M.

Key figures

Revenue (TTM): $2.4M
Revenue growth, 1 year: +52.5%
Net income: −$94.7M
EPS (diluted): −$0.42
Operating margin: -4573.7%

Return on equity: -1423.6%
Return on capital: -104.8%
Debt / equity: 3.68
Current ratio: 3.34
Buyback yield: -56.87%

Key facts

Company value: $164M
Today's range: 0.550.63
Past year's range: 0.351.49

Yesterday's close: $0.59
Swings vs the market: 2.5×bigger